抗血小板薬は主にアテローム血栓症の治療や再発予防に, 抗凝固薬は主に深部静脈血栓症/肺血栓塞栓症や心房細動に用いられている。本研究は血栓症治療薬に特異的な新しい臨床検査指標を包括的に探索開発することを目的とした。
抗血小板薬については脳血管障害, 冠動脈疾患, 周術期患者血栓予防, 心房中隔欠損(ASD)に対するパッチ手術時の血栓予防のための抗血小板薬使用について検討し, 血栓形成能評価法としてPFA-100, VerifyNow, T-TASの意義が示唆された。
抗凝固療法に関しては新規経口抗凝固薬(NOAC)の新たな検査法を検討し, 各凝固検査に対するNOACの特性を十分に考慮する必要性が示唆された。
Antiplatelet drugs are used for the treatment and secondary prevention of atherothrombosis, while anticoagulant drugs are indicated for deep vein thrombosis, pulmonary thromboembolism, and atrial fibrillation. This study aimed for comprehensive exploration and development of new diagnostic markers specific for antithrombotic therapies.
For antiplatelet therapy, cerebrovascular disease, coronary artery disease, and thrombosis prevention in perioperative phases (including patch closure of ASD using clopidogrel) were investigated. PFA-100, VerfyNow, and T-TAS were shown to be effective.
For anticoagulation therapy, novel diagnostic strategies for new oral anticoagulants (NOACs) were examined. Coagulation studies vary significantly between reagents, which should always be taken into consideration when results were interpreted.
|
